FDA Form 483 to Biogen Idec Cites Supplier Quality Issues

Washington Drug Letter
The FDA issued a Form 483 to Biogen Idec that cites a weakness in the way the company manages suppliers, highlighting the difficulties drugmakers continue to have with supplier quality issues.

To View This Article:


Buy This Article Now

Add this article to your cart for $120.00